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Background: Long-term iodine exposure may influence the frequency of thyroid disease 
treatments through fluctuations in thyroid diseases. Yet, the long-term fluctuations in thyroid 
disease treatments upon iodine fortification (IF) are not fully known. We aimed to examine the 
development in thyroid disease treatments in Denmark before and following the implementa-
tion of IF in 2000.
Methods: Nationwide data on antithyroid medication, thyroid hormone therapy, thyroid surgery, 
and radioiodine treatment were obtained from Danish registries. Negative binominal regression 
was applied to analyze annual changes in treatment rates adjusted for region of residence, sex, 
and age.
Results: Incidence of antithyroid medication transiently increased but fell and reached steady 
state from 2010 at an incidence rate ratio (RR) of 0.72 (95% confidence interval [CI] 0.67–0.77) 
compared to year 2000. Thyroid hormone therapy increased and reached steady state in 2010 
at an incidence RR of 1.75 (95% CI 1.62–1.89) compared to year 2000. Thyroid surgery was 
constant except for higher rates in 2014–2015, and radioiodine treatment fluctuated with no 
apparent pattern.
Conclusion: Ten years after IF, a steady state was observed for incident antithyroid medication 
below the level at IF, and thyroid hormone therapy above the level at IF. Only small changes 
were observed in thyroid surgery and radioiodine treatment. In the same period, changes in 
diagnostic and treatment practices and lifestyle factors are likely to have occurred and should 
be considered when evaluating the effects of IF on treatment of thyroid diseases.
Keywords: iodine, pharmacoepidemiology, thyroid diseases
Introduction
The incidence of thyroid disease treatments is affected by the population’s exposure to 
iodine over several years, perhaps decades.1 Iodine fortification (IF) is implemented 
worldwide to improve iodine status,2 but the long-term development in thyroid disease 
treatments after IF and the period until a new steady state is achieved remains to be 
fully established. It is relevant to monitor thyroid disease treatments after IF as part 
of the evaluation of potential effects of IF on the burden of disease on the population 
and the health care system.
The incidence of some thyroid diseases (eg, hyperthyroidism) fluctuates promptly 
and markedly upon IF,3,4 while only minor changes over longer time are observed in 
other thyroid diseases (eg, hypothyroidism).5–7 The incidence of treatments might rapidly 
reflect changes in disease occurrence, whereas the prevalence of medication treatments 
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of longer duration is expected to change more slowly. Fur-
thermore, changes in incident thyroid disease treatments are 
expected to differ between region of residence, sex, and age 
groups. National voluntary IF of salt with 8 ppm iodine was 
implemented in Denmark in 1998, but this proved inefficient8 
and was replaced with mandatory IF of salt with 13 ppm 
iodine in July 2000.9 Eastern and Western Denmark had mild 
and moderate iodine deficiency (ID) before IF, respectively. 
After IF, the population iodine intake was adequate but still 
below the recommended level in specific groups.10 Particu-
larly, women had an overall higher risk of insufficient iodine 
intake and thereby thyroid diseases, and different age groups 
had been exposed to different durations of ID before IF.11
Development in thyroid disease treatment rates does 
not solely depend on IF. Diagnostic activity, indication for 
treatment, treatment aims, health care-seeking behavior, diet, 
alcohol, and smoking may all change over time, and the effect 
on patterns of thyroid disease treatment must be discussed.
The development in incident thyroid disease treatments 
after the implementation of IF in Denmark has previously 
been examined until 2007–2008 but without identification 
of a steady state.12–14 Now, we are able to update with further 
6–8 years of data from nationwide registers with complete 
individual-level information. We previously utilized these 
data to examine the development in costs of thyroid disease 
treatment.15
We aimed to assess the development in annual rates of 
incident thyroid disease treatments (antithyroid medication, 
thyroid hormone therapy, thyroid surgery, and radioiodine 
treatment) during 1995–2015.
Methods
Design and study population
This register-based study included data on all redeemed 
prescriptions, and in- and outpatient hospital treatments 
for thyroid diseases in the entire Danish population during 
1995–2015. Almost all patients with thyroid diseases are 
treated in the tax-funded Danish public health care system, 
and administrative registers contain individual-level infor-
mation on treatments and demographics.16 Linkage between 
registers is possible via the unique personal identification 
number assigned to all Danish citizens.17
Thyroid medication: antithyroid 
medication and thyroid hormone therapy
Information on thyroid medication was obtained from the 
Danish National Prescription Registry, which contains all 
redeemed prescriptions since 1995. Antithyroid medication 
and thyroid hormone therapy were identified by the Anatomic 
Therapeutical Chemical (ATC) classification system codes 
H03B and H03A, respectively, from 1995 to 2015. Prescrip-
tions of thyroid medication following thyroid surgery or 
radioiodine treatment were excluded.
Incident use was defined as a minimum of two redeemed 
prescriptions or 300 defined daily doses (DDD) within 365 
days and no redeemed prescriptions of any thyroid medication 
within the previous 730 days. Incident users were thus only 
defined from 1997. Persons were defined as incident cases 
in the year of the first prescription fulfilling these criteria.
Prevalent use was defined as a minimum of two redeemed 
prescriptions or 300 DDD within 365 days. Persons were 
defined as prevalent cases in all the years these criteria were 
met.
Thyroid surgery
All thyroid surgeries are registered in the Danish National 
Patient Registry. Data on thyroid surgery were obtained 
during 1995–2015 by the Nordic Classification of Surgical 
Procedures codes: 08060–08200 before 1996 and BAA20–
BAA60(A) after 1996. Surgeries performed in one patient 
within 30 days were counted as one surgery. Thyroid sur-
geries classified with a diagnosis of thyroid cancer (ICD-8 
and ICD-10 codes: 19399 and DC739) up to 3 months after 
surgery were excluded.
radioiodine treatment
Radioiodine treatments were registered in the Danish 
National Patient Registry since 2004. Treatments from 2004 
to 2015 were identified by the procedure codes BWGGI 
and WT(F-L)RNJLXX for benign disease. Procedures 
performed in one patient within 90 days were counted as 
one treatment. From 1995 to 2003, number of standard 
doses (600 MBq) used and indication (benign/malignant) 
were reported from the hospital departments to the National 
Institute of Radiation Protection. We defined one standard 
dose as equivalent to one treatment.12 This information 
could not be linked to individual patients, but the location 
of the treating hospital was used as a proxy for region in 
the analyses.
sex, age, and region
Information on sex, date of birth, and region (moderate and 
mild ID before IF) was obtained from the Civil Registration 
System and linked to each redeemed prescription, surgery, 
and radioiodine treatment. Persons over 100 years were 
excluded.
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statistical analyses
Incidence was calculated as the number of incident users 
every year per 100,000 person years (PY). PY was calculated 
as the total population minus the number of prevalent users 
in the previous year. Period prevalence was calculated as the 
number of prevalent users every year per 100,000 persons. 
To adjust for changes in population size and sex and age 
distribution, the treatment rates were standardized to the 
population in 2000 by region by multiplying the relative 
difference in population strata.
Negative binominal regression was applied to estimate 
the incidence and prevalence rate ratios (RRs) between 
calendar years. The Wald Chi-square test was used to test 
for significance. Year 2000 (the year of implementation of 
mandatory IF of salt with 13 ppm iodine) was used as refer-
ence unless otherwise mentioned. The negative binomial 
regression analyses were performed in the unstandardized 
population, and the models adjusted for region, sex, age, 
and the interaction between calendar year and region for the 
figures. The models were further adjusted for the interac-
tion between calendar year and sex and age. The Pearson 
Chi-square test for goodness of fit was >0.8 for all models 
indicating appropriate fits.
All data management and analyses were performed in 
SAS, version 9.4 (SAS Institute Inc, Cary, NC, USA). A 
p-value < 0.05 was defined as statistically significant.
Ethics
According to Danish legislation, approval from the Danish 
Health Research Ethics Committee System is not required for 
studies based solely on registers. Approval from the Danish 
Data Protection Agency was obtained for handling the data 
(journal number 2003-53-0865). All analyses were performed 
at servers at Statistics Denmark with pseudonymized personal 
identification numbers.
Results
The national incidence and prevalence rates of thyroid 
disease treatments per year are displayed in Table 1. The 
corresponding national incidence and prevalence RRs are 
displayed in Table S1.
antithyroid medication
Incident antithyroid medication use increased above the rate 
in the year 2000 during the 2 years following IF but fell below 
since 2005 in the region with moderate ID before IF. In the 
Table 1 national incidence and prevalence rates of treatments for thyroid diseases during 1995–2015
Year Antithyroid medication Thyroid hormone therapy Thyroid 
surgeries
Radioiodine 
treatmentsa
Incidence per 
100,000 PY
Prevalence per 
100,000 persons
Incidence per 
100,000 PY
Prevalence per 
100,000 persons
Per 100,000 
persons
Per 100,000 
persons
1995 – 284.3 – 854.1 24.9 41.6
1996 – 318.8 – 911.3 27.2 46.8
1997 74.8 328.0 80.2 943.6 27.7 47.7
1998b 81.9 342.5 84.6 983.9 27.9 48.1
1999 86.1 361.2 95.6 1032.9 27.9 48.6
2000c 94.1 384.1 98.3 1085.3 29.0 48.2
2001 102.9 415.1 110.6 1146.0 27.2 50.1
2002 98.7 434.3 114.0 1205.2 26.7 48.7
2003 94.4 444.7 122.4 1269.8 27.0 46.1
2004 82.7 441.7 118.0 1326.1 26.4 27.7
2005 78.5 429.0 113.9 1369.1 28.2 29.3
2006 73.5 418.4 128.9 1427.6 27.9 31.0
2007 69.3 407.4 144.7 1494.1 28.3 34.2
2008 68.8 398.4 146.8 1563.6 27.0 22.3
2009 62.5 385.2 150.5 1631.1 32.0 25.1
2010 61.5 374.9 158.0 1700.6 31.9 32.2
2011 57.5 360.2 152.3 1760.4 31.7 34.0
2012 59.5 354.1 146.2 1809.7 29.8 33.5
2013 58.9 343.9 159.6 1865.2 31.9 30.7
2014 57.7 336.8 159.9 1920.4 34.1 30.7
2015 – – – – 35.6 33.1
Notes: standardized for changes in population size, age, and sex distribution. anumber of radioiodine treatment was obtained from the national institute of radiation 
Protection in 1995–2003 and from the Danish National Patient Registry in 2004–2015. bImplementation of voluntary iodine fortification. cimplementation of mandatory iodine 
fortification in July 2000.
Abbreviation: PY, person years.
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
5.
98
.2
16
 o
n 
19
-D
ec
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Epidemiology 2018:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
766
Møllehave et al
region with mild ID before IF, the incidence never rose sig-
nificantly above the rate in the year 2000 and fell below since 
2006. The incidence was constant since 2010–2011 in both 
regions (Figure 1). The incidence was higher in the region 
with moderate ID before IF, in women, and in the oldest age 
group, but these effects decreased over time (Figure S1).
Prevalent antithyroid medication use in both regions rose 
transiently above the rate in the year 2000 but decreased and 
was equal to the rate in the year 2000 since 2007–2008. The 
prevalence was higher in the region with moderate ID before 
IF, in women, and in the oldest age group (Figures S2 and S3).
Thyroid hormone therapy
Incident thyroid hormone therapy use increased during 1997–
2009 and plateaued from 2010 in both regions  (Figure 2). The 
incidence was equal in the regions, but higher in women and 
in the oldest age group. The difference between age groups 
decreased during the study period as the increase in incidence 
was largest below 65 years (Figure S4).
The prevalence increased almost linearly during the 
study period and did not differ between regions. The 
prevalence was higher in women and with increasing age 
(Figures S5 and S6).
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Figure 1 Incidence rate ratios and 95% confidence intervals of antithyroid medication compared to 2000 in (A) the region with moderate ID before IF and (B) the region 
with mild ID before IF.
Notes: The reference year is 2000 (implementation of IF). The analyses were adjusted for region, sex, age, and the interaction between calendar year and region.
Abbreviations: ID, iodine deficiency; IF, iodine fortification.
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Figure 2 Incidence rate ratios and 95% confidence intervals of thyroid hormone therapy compared to 2000 in (A) the region with moderate ID before IF and (B) the region 
with mild ID before IF.
Notes: The reference year is 2000 (implementation of IF). The analyses were adjusted for region, sex, age, and the interaction between calendar year and region.
Abbreviations: ID, iodine deficiency; IF, iodine fortification.
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Thyroid surgery
In the region with moderate ID before IF, the rate of thyroid 
surgery was constant during the study period, but in the region 
with mild ID before IF the rate of surgery was higher in 
2010, 2014, and 2015 vs. 2000 (Figure 3). The rate of thyroid 
surgery was significantly higher in the region with moderate 
ID before IF, in women, and in persons of 40–64 years. The 
increase in recent years was driven by an increase in persons 
of 65+ years (Figure S7).
radioiodine treatment
Trends in radioiodine treatment were evaluated from 2004. 
In the region with moderate ID before IF, rates of radioiodine 
treatment in 2006, 2007, and 2010–2015 were higher than 
in 2004. In the region with mild ID before IF, the rate was 
constant except for 2008 (Figures 4 and S8). Both female 
sex and increasing age were associated with higher rates 
of radioiodine treatment. Only the effect of region changed 
over the years.
Discussion
Incidence of antithyroid medication increased, fell, and 
reached a steady state below the incidence at IF from 2010 
to 2011. Incident thyroid hormone therapy increased until 
it reached a steady state in 2010. For thyroid surgery, we 
observed an increase in recent years in the region with mild 
ID before IF. Whether this increase persists will require more 
years of observation. The rate of radioiodine treatment was 
overall constant with some fluctuations.
For antithyroid medication, the difference in incidence rates 
between regions, sexes, and age groups decreased during the 
study period. An aim of IF is prevention of ID-related diseases 
in vulnerable groups, that is, people in regions with ID, women, 
and young.2 As these groups obtain iodine sufficiency, region of 
residence, sex, and age are expected to have a smaller effect on 
disease outcomes, which is supported by our findings. Thyroid 
function is possibly affected by iodine intake throughout life,1 
and thus, it is plausible that the full effect is not seen until the 
entire population has been iodine sufficient throughout life.
We expected the incidences of treatments to reflect inci-
dences of thyroid diseases in concurrent Danish studies. A 
study based on laboratory databases from 1997 to 2004 also 
found a rise in incident hyperthyroidism,3 and two cross-
sectional studies in 1997–1998 and 2005 observed a decline 
in mild hyperthyroidism18 indicating trends parallel to our 
findings. The transient increase in hyperthyroidism after IF is 
well known and presumably a result of the higher prevalence 
of autonomous thyroid nodules or compensatory mechanisms 
in areas with ID, which will cause an overproduction of thy-
roid hormones after IF. Subsequent iodine sufficiency will 
lower the risk of autonomous thyroid nodules.1
The potential mechanisms behind a rise in hypothyroid-
ism after IF are less clear. It is proposed that susceptible 
individuals may fail to escape the transient downregulation of 
iodine metabolism (ie, the Wolff–Chaikoff effect) after IF.19,20 
Also, IF has been proposed to enhance the risk of thyroid 
autoimmunity.21 Hypothyroidism is predominantly caused 
by autoimmune thyroid disease.22 The prevalence of positive 
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Figure 3 Incidence rate ratios and 95% confidence intervals of thyroid surgery compared to 2000 in (A) the region with moderate ID before IF and (B) the region with 
mild ID before IF.
Notes: The reference year is 2000 (implementation of IF). The analyses were adjusted for region, sex, age, and the interaction between calendar year and region.
Abbreviations: ID, iodine deficiency; IF, iodine fortification.
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thyroid autoantibodies increased from 20% in 1997–1998 to 
32% in 2004–2005 as shown in two cross-sectional studies,23 
and a laboratory study found an incidence RR of hypothy-
roidism of 1.23 (95% confidence interval 1.07–1.42) in 
2003–2005 vs. 1997–1998 driven by an increase primarily 
in the region with moderate ID before IF and the younger 
age groups.5 This does not fully explain the steep increase 
in incident thyroid hormone therapy we observed in both 
regions and the oldest age group. Overall, goiters and nodules 
are treated with surgery and radioiodine depending on size 
and type. Between two cross-sectional studies in 1997–1998 
and 2005, the prevalence of thyroid enlargement fell from 
17.6% to 10.9%.24 However, a longitudinal study from 1997 
to 2008 saw both new appearances and disappearance of 
thyroid nodules.25 This contrasts the constant rate of thyroid 
surgery and radioiodine treatment we observed.
The diagnostic activity for thyroid diseases increased 
and the indication for some treatments may have changed 
during the study period, and thereby affected the treatment 
rates independently from changes in disease rates. The annual 
number of thyroid-stimulating hormone (TSH) measurements 
in the Copenhagen area increased by 164% between 2011 
and 2015,26 and more ultrasound tests were performed in 
other countries and possibly also in Denmark.27,28 This could 
potentially lead to identification of more cases. We found 
no evidence to suggest that the indication for antithyroid 
medication treatment changed during the study period. In 
contrast, Medici et al found that the median TSH at initiation 
of thyroid hormone treatment decreased from 13 mIU/L to 
7.3 mIU/L during 2001–2015.26 This explains a large propor-
tion of the increase in rates of thyroid hormone treatment. 
In Denmark, enlarged thyroid was treated with radioiodine 
or surgery, and hyperthyroidism was treated with antithyroid 
medication, thyroid surgery, or radioiodine.29 However, the 
optimal treatment approach is not always clearly defined, and 
the preferred choice of treatment may have varied through 
the study period and differed between clinicians as observed 
in other countries,28 and could suggest why we do not see 
the expected decline in thyroid surgeries and radioiodine 
treatments.
The ecological study design increases the risk of con-
founding as it is difficult to isolate the effect of IF from 
temporal changes in confounders without individual-level 
data. Potential confounders, beside changes in treatment 
practices, include dietary iodine intake beyond IF, mineral 
interactions, alcohol consumption, smoking, and morbidi-
ties and medication that interfere with iodine or thyroid 
function. Two Danish cross-sectional studies found that 
low-adequate iodine intake was achieved following IF as 
median urinary iodine concentration rose from 61 μg/L 
in 1997–1998 to 97–114 μg/L in 2004–2005.30 However, 
a follow-up of the first study in 2008–2010 found that 
this may not be sustained in women.30,31 Other minerals, 
especially selenium, are also essential for optimal thyroid 
function, and correction of ID may be futile if these are 
deficient.32,33 This is not likely an issue in this study, as 
selenium deficiencies are rare in the Danish population.34 
Alcohol consumption decreased in all age groups dur-
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Figure 4 Incidence rate ratios and 95% confidence intervals of radioiodine treatment compared to 2004 in (A) the region with moderate ID before IF and (B) the region 
with mild ID before IF.
Notes: The reference year is 2004. The analyses were adjusted for region, sex, age, and the interaction between calendar year and region.
Abbreviations: ID, iodine deficiency; IF, iodine fortification.
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ing the study period.35 The percentage of daily smokers 
decreased from 1994 to 2010 in all age groups,36 but this 
trend stagnated37 and smoking may be increasing in the 
youngest age group.38 This can potentially offset the ben-
eficial effects for the first generation in Denmark to grow 
up in iodine sufficiency. Thyroid and gastrointestinal (GI) 
disorders are bidirectionally associated. Iodine malabsorp-
tion and reduced enterohepatic T3 reuptake are risk factors 
for hypothyroidism, and most thyroid diseases present 
with GI symptoms.39 We did not adjust for malabsorption 
because this is inadequately recorded in the registers and 
the direction of causality would be unclear. Lastly, some 
drugs may influence thyroid function, for example, lithium 
and amiodarone.40 The use of lithium in Denmark was rela-
tively constant, while the use of amiodarone increased by 
roughly 10% during the study period.41 The potential effects 
on thyroid disease treatments may therefore be limited.
The main strength is the availability of complete reg-
istry data for all prescriptions and treatments in the total 
Danish population over 20 years, and the ability to adjust 
for individual-level demographic information. The Dan-
ish health registers have a high level of completeness and 
validity which has improved over the past 20 years.42 All 
medications studied require prescriptions, and therefore, a 
high level of completeness is expected. However, registration 
of radioiodine treatment in the National Patient Registry was 
introduced in 2004, and the registration may not have been 
fully accurate during the first years.
Conclusion
Ten years after IF, a steady state was observed for incident 
antithyroid medication below the level at IF, and thyroid hor-
mone therapy above the level at IF. Only small changes were 
observed in thyroid surgery and radioiodine treatment. In the 
same period, changes in diagnostic and treatment practices 
and lifestyle factors are likely to have occurred and should 
be considered when evaluating effects of IF.
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